TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts..

佛罗里达州坦帕市（BUSINESS WIRE）-Oragenics，Inc。（NYSE American:OGEN）（“Oragenics”或“Company”）和Lantern Bioworks宣布开创性的合作伙伴关系，其标志是材料转让协议的正式化。这一里程碑遵循对Oragenics生物样本的严格测试和验证，这些样本有望通过用非致病性对应物替换有害细菌菌株来彻底改变龋齿预防。。

Under this agreement, Oragenics has received a cash payment of $50,000 alongside an enticing opportunity to acquire one million shares of Lantern Bioworks’ equity. Additionally, Lantern Bioworks has committed to pay Oragenics a ten percent (10%) royalty on the net income generated from any products stemming from the transferred assets.

根据该协议，Oragenics已获得5万美元的现金支付，同时还有一个诱人的机会收购100万股Lantern Bioworks的股权。此外，Lantern Bioworks已承诺向Oragenics支付由转移资产产生的任何产品产生的净收入的10%（10%）特许权使用费。

The royalty payments span a ten (10)-year term..

特许权使用费支付期限为十（10）年。。

Kim Murphy, the President and Chief Executive Officer of Oragenics, expressed enthusiasm, stating, “We are elated to witness these assets continue their journey, contributing to the scientific legacy that Oragenics has cultivated over many years. Dental caries remains a pervasive global oral health challenge, and replacement-therapy approach holds immense promise in offering enduring protection against this disease.”.

Oragenics的总裁兼首席执行官Kim Murphy表示热情，“我们很高兴看到这些资产继续前进，为Oragenics多年培养的科学遗产做出了贡献。龋齿仍然是全球普遍存在的口腔健康挑战，替代疗法在提供持久的抗这种疾病保护方面具有巨大的希望。”。

Of importance to note, these samples remain distinct from Oragenics’ current or ongoing research endeavors, specifically in the realms of Lantibiotics or SARS-CoV-2 vaccine candidates. Instead, they originated from a prior research and development project that Oragenics had temporarily suspended, awaiting an opportune application..

值得注意的是，这些样本与Oragenics目前或正在进行的研究工作截然不同，特别是在羊毛硫抗生素或SARS-CoV-2候选疫苗领域。相反，它们起源于先前的研究和开发项目，Oragenics暂时暂停，等待适当的应用。。

Lantern Bioworks has demonstrated a keen interest in harnessing the potential of these samples to fortify their ongoing product development initiatives.

Lantern Bioworks表现出对利用这些样本的潜力来加强其正在进行的产品开发计划的浓厚兴趣。

Crucially, this agreement does not entail the transfer of intellectual property ownership from Oragenics to Lantern Bioworks.

至关重要的是，本协议不涉及将知识产权所有权从Oragenics转移到Lantern Bioworks。

About Oragenics

关于Oragenics

Oragenics, Inc. is a development-stage company focused on nasal delivery of pharmaceutical medications including in neurology and fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.

Oragenics，Inc。是一家开发阶段的公司，专注于鼻腔给药，包括神经病学和抗击传染病，包括冠状病毒和耐多药生物。其主要产品是NT-CoV2-1，一种预防COVID-19和SARS-CoV-2病毒变体的鼻内候选疫苗。

The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its Lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

NT-CoV2-1计划利用美国国立卫生研究院（NIH）和加拿大国家研究委员会（NRC）许可的冠状病毒刺突蛋白研究，重点是减少病毒传播并提供更具患者友好性的鼻内给药。其羊毛硫抗生素计划的特点是一类新型抗生素，可抵抗对商业抗生素产生耐药性的细菌。

For more information, please visit www.oragenics.com.

欲了解更多信息，请访问www.oragenics.com。

Forward-Looking Statements

前瞻性声明

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements.

本通讯包含1995年“美国私人证券诉讼改革法案”安全港条款范围内的“前瞻性声明”。这些前瞻性陈述基于管理层的信念，假设和当前可用的信息。“相信”，“期待”，“预期”，“打算”，“估计”，“项目”等词语以及与历史事项无关的类似表达方式可以确定前瞻性陈述。

Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: Lantern Bioworks ability to successfully develop and commercialize the transferred assets; Lantern Bioworks ability to generate net income from any products stemming from the transferred assets; uncertainties related to the value of Lantern Bioworks should Oragenics elect to purchase equity of Lantern Bioworks; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S.

投资者应该谨慎依赖前瞻性陈述，因为它们受到各种风险，不确定性和其他可能导致实际结果与任何此类前瞻性陈述中表达的结果大不相同的因素的影响。这些因素包括但不限于以下内容：Lantern Bioworks成功开发和商业化转移资产的能力；Lantern Bioworks能够从转移资产产生的任何产品产生净收入；如果Oragenics选择购买Lantern Bioworks的股权，与Lantern Bioworks价值相关的不确定性；以及一般的经济和市场条件和风险，以及我们与美国的文件中描述的其他不确定性。

Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law..

证券交易委员会。本新闻稿中列出的所有信息自本新闻稿发布之日起。您应该在评估本新闻稿中包含的前瞻性陈述时考虑这些因素，而不是过分依赖这些陈述。除法律另有要求外，我们不承担任何义务公开提供任何前瞻性声明的修订或更新，无论是由于新信息，未来发展还是其他原因，情况是否会发生变化。。